Watch the NEJM Quick Take of these two open-label, randomized, controlled trials.
Nirmatrelvir–ritonavir reduced the risk of hospitalization or death related to Covid-19 in unvaccinated, higher-risk patients. However, effectiveness in immune populations is unclear. New research is summarized in a short video.